乙酰半胱氨酸药用联合双水平气道正压通气治疗重叠综合征的疗效

目的研究乙酰半胱氨酸药用联合双水平气道正压通气治疗重叠综合征的疗效。方法选取2013年7月至2015年3月期间本院收治的88例重叠综合征,按照随机数表法分为观察组和对照组,每组44例。对照组采取双水平气道正压通气,观察组在对照组基础上联合乙酰半胱氨酸药用。比较两组患者治疗后的临床疗效和治疗前后血清、肺功能及血气指标变化。结果治疗后,观察组患者总的有效率为93.18%(41/44)明显比对照组高77.27%(34/44),差异具有统计学意义(P0.05);观察组的SOD(51.21±3.01)u U/L、IL-6(5.03±1.11)ng/L指标要明显比对照组低(65.93±3.12)u U/L、(6.74±1.22)ng/L,观察组的IL-8(10.21±2.21)ng/L要高于对照组(7.32±1.54)ng/L,差异具有统计学意义(P0.05);观察组的FEV1、FEV1%、FEV1/FVC、FVC肺功能指标分别为(1.97±0.49)L、(54.33±12.46)%、(54.56±6.07)%、(54.21±10.31)%,高于对照组(P0.05);观察组的PaCO_2(32.14±5.01)mm Hg低于对照组(36.32±5.32)mm Hg,PaO_2(82.32±5.21)mm Hg高于对照组(73.21±4.76)mm Hg。结论重叠综合征患者采取乙酰半胱氨酸药用并联合双水平气道正压通气进行治疗,患者的血清指标、血气情况及肺功能均可得到明显的改善,临床疗效较好。

Clinical effect of acetylcysteine pharmaceutical combined with bi-level positive airway pressure on overlap syndrome disease patients

Objective To study the clinical effect of acetylcysteine pharmaceutical combined with bi-level positive airway pressure on overlap syndrome disease patients. Methods 88 patients with overlap syndrome from Ju-ly 2013 to March 2015 in our hospital were randomly divided into the observation group and the control group. The control group received bi-level positive airway pressure,and the observation group was given acetylcysteine pharma-ceutical on the basis of the control group. They were compared with the clinical efficacy after treatment,and their ser-um,lung function and blood gas before and after treatment were also compared. Results After treatment,the total effective rate was 93. 18%(41 / 44)in the observation group,significantly higher than 77. 27% in the control group (34 / 44)(P < 0. 05). The levels of SOD and IL-6 were(51. 21 ± 3. 01)uU/ L and(5. 03 ± 1. 11)ng/ L in the observation group,which were both significantly lower than those in the control group[(65. 93 ± 3. 12)uU/ L, (6. 74 ± 1. 22)ng / L](P < 0. 05). The level of IL-8 was(10. 21 ± 2. 21)ng/ L in the observation group and (7. 32 ± 1. 54)ng/ L in the control group(P < 0. 05). The value of FEV1 ,FEV1% ,FEV1 / FVC and FVC were (1. 97 ± 0. 49)L,(54. 33 ± 12. 46)% ,(54. 56 ± 6. 07)% ,and(54. 21 ± 10. 31)% respectively in the observation group,all higher than those in the control group(P < 0. 05). The levels of PaCO2 and PaO2 was(32. 14 ± 5. 01) mmHg and(82. 32 ± 5. 21)mmHg in the observation group,and(36. 32 ± 5. 32)mmHg and(73. 21 ± 4. 76) mmHg in the control group. Conclusion Acetylcysteine pharmaceutical combined with bi-level positive airway pres-sure can improve the patient’s serum markers,blood gas and pulmonary function,and have a good clinical efficacy in treatment of overlap syndrome disease patients.